This roundtable series delves into therapies used for late-stage small and non–small cell lung cancer as discussed by participants at virtual live events.
Reviewing OPAL Results in EGFR+ NSCLC Before Phase 3 FLAURA2 Presentation
August 22nd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Martin F. Dietrich, MD, PhD, discussed the phase 2 data for osimertinib plus chemotherapy in EGFR-mutated non–small cell lung cancer and what they suggest for the upcoming phase 3 FLAURA2 trial results.
FLAURA Data Provides Insight on Sequencing Therapy for EGFR+ NSCLC
September 14th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Martin F. Dietrich, MD, discussed subgroup analysis and safety of osimertinib based on the FLAURA trial. This is the second of 2 articles based on this event.